Last reviewed · How we verify
Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation
Approved treatments
- Mekinist · Novartis
Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation patent landscape — cliff calendar, originator estates, attackable patents
- Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation treatment landscape brief
- Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation treatment updates RSS
Frequently asked questions about Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation
What drugs treat Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation?
Tracked treatments include Mekinist.
What is the treatment for Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation?
Standard treatment for Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation includes Mekinist. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation patent cliff · Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation CI report
- Treatment: Mekinist · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing